Founded in Hangzhou in 2025, ReHealth AI is building the infrastructure to solve preventive medicine's core commercialization challenge — converting intervention outcomes into causal evidence accepted by healthcare payers. We're not another health management company. We're the infrastructure that makes health management billable.
"Prevention is better than cure" is medicine's oldest consensus, but it has never been translated into payer language. Our mission: give prevention a price tag through verifiable causal evidence that makes payers willing to pay.
We don't build health apps, checkup platforms, or wearables. We build the underlying infrastructure that chains all their data into causal pathways and converts it into billable evidence. Electricity isn't an appliance; Alipay isn't a store — ReHealth AI is preventive medicine's "payment rail."
The market is flooded with "participants are healthier" correlation data, but payers don't pay. We use PSM to eliminate selection bias and quantify true causal effects. Causal evidence is our core barrier and the industry's inevitable path.
Under federated learning, raw patient data never leaves the institution. Differential privacy protects model gradients. Triple-law compliance isn't a competitive advantage — it's the minimum standard for medical AI. We've built to this standard from day one.
Our team covers AI algorithms, clinical medicine, and medical device commercialization end-to-end — from model R&D to regulatory registration to commercial deployment.
Federated learning: raw patient data stays on-premise at all times.
Compliant with PIPL, DSL, and CSL.
Attribution design references real-world study methodology; drug or device registration submissions require separate work under applicable NMPA requirements.
Covering prediction, FL, attribution, and settlement.
Medical device software registration in progress.
Seed round closed with strategic healthcare investor.
Hangzhou, Zhejiang, China
Whether you're a hospital, insurer, employer, or pharma company, ReHealth Core provides full closed-loop support from prediction to settlement.
Founded in 2025, ReHealth AI focuses on solving the core bottleneck in preventive medicine commercialization: turning intervention outcomes into auditable causal evidence for payer evaluation. Core team from UCL, Harvard Medical School, and Alibaba DAMO Academy.